Net revenue for the company’s prescription prenatal vitamin business
was approximately $4.3 million for the second quarter of 2017 compared
with approximately $4.4 million for the second quarter of 2016.

Net loss was approximately $19.7 million for the second quarter of
2017, compared with approximately $21.1 million for the second quarter
of 2016.

Ended the quarter with approximately $96.5 million in cash and no debt.

Participated in a Type A Post-Action Meeting on June 14, 2017 with the
Division of Bone, Reproductive, and Urologic Products (DBRUP) of the
FDA to discuss the Complete Response Letter (CRL) regarding the New
Drug Application (NDA) for TX-004HR, the company’s investigational
applicator-free estradiol vaginal softgel capsule for the treatment of
moderate-to-severe vaginal pain during sexual intercourse
(dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to
menopause. The Company has formally submitted additional information
for consideration related to the NDA for TX-004HR and has been
informed by the FDA that it will be receiving an Advice Letter within
the next week outlining the FDA’s timing of its review of the
submitted additional data.

Pre-NDA meeting for TX-001HR, the company’s investigational
bio-identical hormone therapy combination of estradiol and
progesterone in a single, oral softgel for the treatment of
moderate-to-severe vasomotor symptoms due to menopause, scheduled with
the FDA at the end of August 2017. The company anticipates that it
will submit the NDA for TX-001HR in the fourth quarter of 2017.

Dismissal without prejudice of the primary federal securities class
action lawsuit recently filed against the company.

Grew the company’s intellectual property portfolio to a current total
of 158 patent filings, including 82 international filings, with one
allowed and 17 issued U.S. patents.

Net revenue from the company’s prescription prenatal vitamin business
was approximately $4.3 million for the second quarter of 2017 compared
with net revenue of approximately $4.4 million for the prior year’s
quarter. These changes were primarily due to a decrease in the number of
units sold.

Cost of goods sold was approximately $0.7 million for the second quarter
of 2017, compared with approximately $1.1 million for the prior year’s
quarter.

Total operating expenses for the second quarter of 2017 included
research and development (R&D) expenses and sales, general, and
administrative expenses (SG&A). R&D expenses for the second quarter of
2017 were approximately $8.7 million compared with approximately $13.8
million for the prior year’s quarter. The decrease in R&D expenses was a
direct result of the completion of the REPLENISH Trial for TX-001HR.
SG&A expenses for the second quarter of 2017 were approximately $14.6
million compared with approximately $10.6 million for the prior year’s
quarter, primarily due to higher sales, marketing, regulatory
expenditures, and personnel costs to support future commercialization.

Net loss for the second quarter of 2017 was approximately $19.7 million,
or $0.10 per basic and diluted share, compared with approximately $21.1
million, or $0.11 per basic and diluted share, for the second quarter of
2016.

At June 30, 2017, cash on hand was approximately $96.5 million, compared
with approximately $131.5 million at December 31, 2016.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s late stage clinical pipeline includes two phase 3 product
candidates: TX-001HR for treatment of moderate-to-severe vasomotor
symptoms (VMS) due to menopause and TX-004HR for treatment of
moderate-to-severe vaginal pain during sexual intercourse (dyspareunia),
a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The
company also manufactures and distributes branded and generic
prescription prenatal vitamins under the vitaMedMD® and
BocaGreenMD® brands.